Abstract
Vigabatrin is an efficacious new-generation antiepileptic drug, but visual field loss (VFL) has strongly limited its use. A systematic review has established that vigabatrin increases the risk of VFL fourfold, with age and exposure as predicting factors. For infantile spasms, the benefits of vigabatrin seem to outweigh the VFL risk.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
